Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer

摘要

Background: The benefit chemotherapy for patients with liver metastases cancer remains unclear. We evaluated preoperative chemotherapy with bevacizumab in and attempted to identify clinical predictors o-alive octal efficacy of such patients, recurrence. Patients and Methods: Between February 2007 and December 2013, a total of 65 liver resections for colorectal metastases were performed at our Institution; 47 patients underwent preoperative chemotherapy, which consisted of modified FOLFOX6 (mFOLFOX6) in 42 cases. The last clinical follow tip was in December 2014. Demographic and clinicopathological factors were reviewed for each patient, and potential predictors of recurrence after liver resection were evaluated. Disease free survival (DES) and overall survival (OS) were compared with respect to clinicopathological factors. Results: The 3- and 5-year OS rates were 73.9% and 62.5%, respectively. The time at which metastases appeared, and the extent of metastasis according to the Japanese classification did not significantly affect OS or DES. However, mEOLEOX6 plus bevacizumab significantly improved DES compared to mFOLFOX6 alone. Patients did not experience worsening of hepatic dysfitnction during preoperative chemotherapy, and tolerated surgical stress well. Conclusion: Preoperative chemotherapy with bevacizumab appears to be an effective treatment modality for liver metastases from colorectal cancer, and results in prolonged DFS.